Texas markets

VolitionRx Limited will host Capital Markets Day on Friday 13th May

AUSTIN, TX, May 5, 2022 /PRNewswire/ — VolitionRx Limited VNRX (“Volition”), a multinational epigenetics company, plans to hold a capital markets day in a hybrid format on Friday, May 13, 2022, at 10am US Eastern Time. Volition’s leadership team will provide strategic updates and discuss the company’s key near-term growth drivers.

Event: VolitionRx Limited Capital Markets Day
Date: Friday, May 13, 2022
Weather: 10:00 a.m. Eastern Time
Location in person: Siebert RoomNew York Stock Exchange
To attend in person, contact [email protected]
To attend virtually please register HERE

Company presentations will cover:

Naked.Q® Veterinary

  • Veterinary market opportunity (reference laboratory and point of service)
  • Heska License Agreement (up to $28 million in milestone payments PLUS ongoing revenue for tests sold)
  • Other License Updates
  • New Product Updates

Naked.Q® NET

  • Clinical results to date
  • Clinical and regulatory plan, including FDA schedules
  • Market opportunity

– Financial Update: Key Measures and Considerations

A Q&A session with management will follow the prepared remarks and formal presentation.

To attend the event in person, please contact [email protected]

To access the virtual event, register by clicking on HERE.

The event will be webcast and presentations will be posted on the Volition website. A replay will be made available.

For more information or questions, please contact Investor Relations at [email protected] or call 646 650 1351

Volition develops simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including cancer in humans and animals. For more information on Volition’s Nu.Q® technology, visit: www.volition.com

About Will

Volition is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and follow-up have the potential not only to prolong patients’ lives, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids – an indication that disease is present. Volition primarily focuses on human diagnostics and monitoring, but also has a subsidiary focused on animal diagnostics and monitoring.

Volition’s research and development activities are centered on Belgiumwith an innovation laboratory in California and additional offices at Texas, Londonand Singaporeas the company focuses on bringing its disease diagnostic and monitoring products to market.

For more information about Volition, visit Volition’s website or contact us through Twitter, LinkedInand Facebook.

Media inquiries:

Louise Batchelor/Debra DaglichVolition, [email protected] +44 (0)7557 774620

Investor requests:

Scott PowellVolition, [email protected] +1 (646) 650 1351

Show original content:https://www.prnewswire.com/news-releases/volitionrx-limited-to-host-capital-markets-day-on-friday-may-13-301540753.html

SOURCE VolitionRx Limited